Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Grignon

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 8, 2011
Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05)Colleen A Lawton, Daniel Hunt, W Robert Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 22, 2004
Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoproteinHind Nassar, Vishali Pansare, Hongquan Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|April 10, 2010
Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancerMack Roach, Kyounghwa Bae, Colleen Lawton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2008
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610Mack Roach, Kyounghwa Bae, Joycelyn Speight, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31Miljenko V Pilepich, Kathryn Winter, Colleen A Lawton, et al.
World Journal of Urology|September 16, 2018
SIU-ICUD on bladder cancer: pathologyEva Compérat, Marek Babjuk, Ferran Algaba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202Arnab Chakravarti, Michelle DeSilvio, Min Zhang, et al.
The American Journal of Pathology|January 27, 2004
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motilityDaotai Nie, Mingxin Che, Alex Zacharek, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2005
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology GroupArnab Chakravarti, Kathryn Winter, Chin-Lee Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 2007
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trialMack Roach, Michelle De Silvio, Timothy Rebbick, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
International Journal of Radiation Oncology, Biology, Physics|April 8, 2011
Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05)Colleen A Lawton, Daniel Hunt, W Robert Lee, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 22, 2004
Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoproteinHind Nassar, Vishali Pansare, Hongquan Zhang, et al.
International Journal of Radiation Oncology, Biology, Physics|April 10, 2010
Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancerMack Roach, Kyounghwa Bae, Colleen Lawton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2008
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610Mack Roach, Kyounghwa Bae, Joycelyn Speight, et al.
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31Miljenko V Pilepich, Kathryn Winter, Colleen A Lawton, et al.
World Journal of Urology|September 16, 2018
SIU-ICUD on bladder cancer: pathologyEva Compérat, Marek Babjuk, Ferran Algaba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2007
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202Arnab Chakravarti, Michelle DeSilvio, Min Zhang, et al.
The American Journal of Pathology|January 27, 2004
Differential expression of thromboxane synthase in prostate carcinoma: role in tumor cell motilityDaotai Nie, Mingxin Che, Alex Zacharek, et al.
International Journal of Radiation Oncology, Biology, Physics|May 14, 2005
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology GroupArnab Chakravarti, Kathryn Winter, Chin-Lee Wu, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 2007
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trialMack Roach, Michelle De Silvio, Timothy Rebbick, et al.
Pageof 5